Surveying Mutation of FLT3 Genes in Children with Acute Leukemia

Surveying Mutation of FLT3 Genes in Children with Acute Leukemia

Background and purpose: Mutation of FMS like tyrosine kinase (flt3) gene causes uncontrolled proliferation of leukemic cells and a bad prognosis. The present study is aimed at implementing molecular tests to diagnose and screen the mutations in acute leukemia patients. Methodology: Totally, 91 chil...

Full description

Bibliographic Details
Main Authors:	Maryam Sheikhi, Farhad Zaker, Gholamreza Javadi, Mehrdad Hashemi, Farnaz Razmkhah, Abolfazl Movafagh
Format:	Article
Language:	English
Published:	West Asia Organization for Cancer Prevention 2017-02-01
Series:	Asian Pacific Journal of Cancer Care
Subjects:	acute leukemia, flt4 gene, itd mutation, point mutation d835
Online Access:	http://www.waocp.com/journal/index.php/apjcc/article/view/11

Similar Items

Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients
by: Ender Coşkunpınar, et al.
Published: (2012-08-01)

Incidence and clinical significance of FLT3 and nucleophosmin mutation in childhood acute myeloid leukemia in Chile
by: Maria Elena Cabrera, et al.
Published: (2023-01-01)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
by: Mariko Takenokuchi, et al.
Published: (2012-10-01)

The Impact of <i>Flt3</i> Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis
by: Gledson L. Picharski, et al.
Published: (2019-09-01)

Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis
by: Mamdooh Gari, et al.
Published: (2008-11-01)

Evaluating the clinical significance of FLT3 mutation status in Syrian newly diagnosed acute myeloid leukemia patients with normal karyotype
by: Yahia Moualla, et al.
Published: (2022-11-01)

Frequency of FLT3/ITD Mutation in Patients with Acute Myeloid Leukaemia presenting at Combined Military Hospital, Rawalpindi
by: Anil Babar, et al.
Published: (2023-12-01)

Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors
by: Deniz Yılmaz Karapınar, et al.
Published: (2015-07-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)

fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007- 2008
by: Amir Hossein Emami, et al.
Published: (2009-12-01)

fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007- 2008
by: Amir Hossein Emami, et al.
Published: (2009-10-01)

<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
by: Andrew Y. Li, et al.
Published: (2021-03-01)

CPX-351 in FLT3-mutated acute myeloid leukemia
by: Claire Andrews, et al.
Published: (2023-11-01)

The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
by: Long Su
Published: (2019-02-01)

Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
by: Sarah Bertoli, et al.
Published: (2020-03-01)

FLT3 Mutation as a Significant Prognostic Marker in de novo Acute Myeloid Leukemia Patients: Incidence, Distribution and Association with Cytogenetic Findings in a Study from South India
by: Santhi Sarojam, et al.
Published: (2014-10-01)

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach
by: Abeer M. Al-Subaie, et al.
Published: (2021-07-01)

FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
by: Ying Wang, et al.
Published: (2018-05-01)

Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01)

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
by: Kateryna Fedorov, et al.
Published: (2023-04-01)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
by: Xinhua Xiao, et al.
Published: (2023-11-01)

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory <i>FLT3</i>-ITD Mutation-Positive Acute Myeloid Leukemia
by: David Martínez-Cuadrón, et al.
Published: (2022-06-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
by: Belen Lopez-Millan, et al.
Published: (2022-03-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
by: Rosa Ayala, et al.
Published: (2022-11-01)

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of <i>FLT3</i>-Mutated Acute Myeloid Leukemia
by: Shuangshuang Wu, et al.
Published: (2022-09-01)

FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
by: Eugenio Galli, et al.
Published: (2024-02-01)

Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China
by: Enbo Chen, et al.
Published: (2023-12-01)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
by: Sebastian Scholl, et al.
Published: (2020-11-01)

An HSP90 Inhibitor Overcomes FLT3 Inhibitor Resistance in FLT3/ITD-Positive Leukemia Cells with an N676K Mutation
by: Hiraku Ogata, et al.
Published: (2023-09-01)

Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
by: Pierre-Yves Dumas, et al.
Published: (2020-07-01)

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
by: Bo-Reum Kim, et al.
Published: (2020-06-01)

Comparison of fragment analysis and PCR electrophoresis methods for the detection of FLT3‑ITD mutations in patients with acute myeloid leukemia
by: I. E. Maslyukova, et al.
Published: (2022-11-01)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
by: Tobias R. Haage, et al.
Published: (2023-05-01)

The Clinical Utility of <i>FLT3</i> Mutation Testing in Acute Leukemia: A Canadian Consensus
by: Julie Bergeron, et al.
Published: (2023-12-01)

The specific features of the immunophenotype of blast cells in patients with de novo normal karyotype acute myeloid leukemia and FLT3-ITD mutation
by: S V Gritsaev, et al.
Published: (2014-03-01)

Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations
by: Fei Li, et al.
Published: (2018-05-01)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
by: Tecik M, et al.
Published: (2022-11-01)